NOTCH1 and acute lymphoblastic leukemia: SERCA inhibitors have been identified as potential regulators of mutant NOTCH1 signaling associated with leukemogenesis, functioning by modulating cell cycle progression, and the expansion of T-ALL xenograft models [58].